Drug Profile
KP 772
Alternative Names: FFC 24; KP772Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Faustus Forschungs Compagnie
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Austria
- 07 Dec 2005 Preclinical trials in Cancer in Austria (unspecified)